新日本科学（2395） – Supplementary Material on Quarterly Financial Results

Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.The 3rd Quarter of the Fiscal Year Ending March 31, 2022SupplementaryMaterial on Quarterly Financial ResultsFebruary 2, 2022（TSE 1stSection:2395）Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.11. Outline of Q3 Consolidated Financial ResultsCopyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.2104.2129.416.446.8FY21/3Q3FY22/3Q3FY21/3Q3FY22/3Q3Ordinary ProfitNet salesFinancial Results Highlights: Q3 FY2022/3Set new record highs againfor operating profit, ordinary profit and profit attributable to owners of parent売上高129.4+25.2営業利益33.0+16.7経常利益46.8+30.3親会社株主に帰属する当期純利益52.4+37.72022年3月期３Ｑ実績前年同期比Net salesOperating ProfitOrdinary ProfitProfit Attributable to Owners of ParentYoyFY2022/3Q3Results（100 million of yen）（100 million of yen）Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.3前臨床事業国内臨床事業(新日本科学PPD含む)2022年3月期３Ｑ39.29.3-4.90.14.9-1.846.82021年3月期３Ｑ22.46.2-4.5-0.4-5.0-2.316.4前年同期比増減額+16.8+3.1-0.4+0.5+9.9+0.4+30.3経常利益合計CRO事業トランスレーショナルリサーチ事業メディポリス事業為替差損益その他Yoy Comparison ofConsolidated Ordinary Profit & Loss: Q3FY2022/3Ordinary profit totalOtherMedipolis businessTranslationalResearch businessCRO businessPreclinicalClinical (incl. PPD-SNBL)Foreign exchange profit and lossQ3 FY2022/3 Q3FY2021/3 Yoy changes As of 31/12/20205.31 stronger yen ⇒FX loss of 500million yenAs of 31/12/2021 4.30 weaker yen ⇒FX profit of 490million yen（100 million of yen）FY22/3Q3FY21/3Q3PreclinicalClinical (incl. PPD-SNBL)TranslationalResearchMedipolis FX profit and lossOther16.4+16.846.8JPY 3.03 bn+3.1▲0.4+0.5+9.9+0.4Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.42. Revisions to Full-year Forecasts for FY2022/3(announced on Feb2, 2022)Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.5Revisions to Full-year Forecasts for FY2022/3 announced on Feb 22022Again we expect to achieve new record highsfor operating profit, ordinary profit and profit attributable to owners of parent Assumed FX rate: 111.95 JPY/USDCompany posted foreign exchange profit of 490 million yen in loan to subsidiary in Q3. However, assumed exchange rate of 115.01 yen/USD is maintained as that of the end of December 2021.（100 million of yen）前回予想（2021/10/21開示）売上高151.1174.0179.0+5.0+27.8営業利益25.238.041.0+3.0+15.7経常利益36.446.056.3+10.3+19.8親会社株主に帰属する当期純利益36.649.058.0+9.0+21.32021年3月期今回修正予想（2022/2/2開示）前回(10/21)予想比前期比2022年3月期Net salesOperating ProfitOrdinary ProfitProfit Attributable to Owners of ParentFY2022/3FY2021/3ResultsPrevious forecasts(21/10/2021)New forecasts(2/2/2022)YoyChanges against original forecastsCopyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.646.0+0.656.3+4.3▲0.1+0.0+3.4+2.1前臨床国内臨床(新日本科学PPD含む)為替差損益その他2022年3月期当初予想2022年3月期今回予想メディポリストランスレーショナルリサーチPrevious forecasts1.24 weaker yen ⇒FX profit of 150million yen (assumed FX fate : 111.95JPY/USD)New forecasts4.30 weaker yen ⇒FX profit of 490million yen (assumed FX fate : 115.01JPY/USD)Comparison ofConsolidated Ordinary Profit & Loss Forecasts against Previous Plan FY2022/3（100 million of yen）前臨床事業国内臨床事業(新日本科学PPD含む)参考）2021年3月期実績34.310.0-7.0-0.52.3-2.736.42022年3月期今回予想52.311.8-8.30.04.9-4.456.32022年3月期前回予想51.77.5-8.20.01.5-6.546.0前回予想比増減額+0.6+4.3-0.1+0.0+3.4+2.1+10.3経常利益合計CRO事業トランスレーショナルリサーチ事業メディポリス事業為替差損益その他Ordinary profit totalOtherMedipolis businessTranslationalResearch businessCRO businessPreclinicalClinical (incl. PPD-SNBL)Foreign exchange profit and lossNew forecasts FY2022/3 Original forecasts FY2022/3Changes against originalplan Ref.) Results FY2021/3FY22/3New forecastsFY22/3Previous forecastsPreclinicalClinical (incl. PPD-SNBL)TranslationalResearchMedipolis FX profit and lossOtherJPY 1.03 bnCopyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.73. ReferencesCopyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.8CRO Business:Contracts in Preclinical Servicesin Q3 FY2022/3101.095.1116.7175.6100.9116.5136.8190.740.060.080.0100.0120.0140.0160.0180.0200.00.020.040.060.080.0100.0120.0140.0160.0180.0’19/3期3Q’20/3期3Q’21/3期3Q’22/3期3Q受注高受注残高受注高（単位:億円）Backlog（x100M JPY）Contract Amount(x100M JPY)ContractsReceivedBacklogFY22/3Q3FY21/3Q3FY20/3Q3FY19/3Q3Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.9CRO Business:Trend of Biopharmaceutical Contracts in Preclinical Services■Number of development candidates for biopharmaceuticals excluding small moleculesAlmost an equal number of cadidateswere recorded in 2021 as the previous year.Vaccines and peptide candidates on the rise.■Number of biopharmaceuticals-related studies excluding small moleculesSNBL conducted 719 studies (+42.7% yoy)) in 2021, of which 253 were GLPstudies (+50.6% yoy). Antibodies and nucleic acid medicines are on the increase. YearGuideline of Nonclinical Studies for Prevention of Infectious Diseases2010Guidance for Peptide Vaccines for Cancer Treatments2012Consideration Paper Re. Nonclinical Safety Studies for Therapeutic Peptide Vaccines 2014White Paper Concerning Quality Control and Nonclinical Safety Evaluation of Nucleic Acid Medicines2016Ministerial Ordinance Concerning Conducing of Nonclinical Safety Studies of Regenerative Medicine Products2014Guideline for Nonclinical Safety Evaluation of Nucleic Acid Medicines2020CellNucleic AcidVaccinePeptideProteinAntibodyBacteria/virusNumber of development candidates outsourced to SNBL Copyright© 2021 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.株式会社新日本科学Copyright© 2022 SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. All rights reserved.10Cautionary Notes＜IRInquiries＞Shin Nippon Biomedical Laboratories, Ltd. Corporate Communications DepartmentPhone:+81 03-5565-6216E-mail:ir@snbl.co.jpWebsite:https://www.snbl.co.jp1.ProjectedresultsarebasedoninformationavailabletotheCompanyatthetimeofwriting,aswellascertainassumptionsjudgedbytheCompanytobereasonable.Variousrisksanduncertainfactorscouldcauseactualresultstodiffermateriallyfromtheseprojections.ThismaterialdoesnotconstituteasolicitationofapplicationtoacquireoranoffertosellanysecurityinJapanorelsewhere.ThismaterialispresentedtoinformstakeholdersoftheviewsofSNBL’smanagementbutshouldnotbereliedonsolelyinmakinginvestmentandotherdecisions.Youshouldrelyonyourownindependentexaminationofusbeforeinvestinginanysecuritiesissuedbyourcompany.SNBLshallacceptnoresponsibilityorliabilityfordamageorlosscausedbyanyerror,inaccuracy,misunderstandingorchangesoftargetfiguresoranyotheruseofthismaterial.2.Informationaboutpharmaceuticalproducts(includingproductscurrentlyindevelopment)includedinthismaterialisnotintendedtoconstituteanadvertisementnormedicaladvice.3.Thepresentationslidesarebasedon”SummaryofConsolidatedFinancialResultsfortheThirdQuarteroftheFiscalYearEndingMarch31,2022(JapaneseGAAP).“Figuresroundedtothenearest100millionJPYandpercentagetoonedecimalplace.4.ThisEnglishpresentationwastranslatedfromtheoriginalJapaneseversion.Intheeventofanyinconsistencybetweenthestatementsinthetwoversions,thestatementsintheJapaneseversionshallprevail.(In millions of yen)2017/3 2018/32019/32020/32021/32022/3ForecastsRevenue17,24416,60015,65814,56115,11017,900 y/y change16.9%-3.7%-5.7%-7.0%3.8%18.5%Gross profit4,3605,2046,1777,6157,5549,656 Gross profit ratio25.3%31.3%39.5%52.3%50.0%53.9%Operating profit-1,792-6978292,2282,5294,100 y/y change(cid:695)(cid:695)(cid:695)168.5%13.5%62.1% Equity method investment gains (losses)12637361888846Ordinary profit-2,105-8131,6133,1213,6455,630 Profit before income taxes-764-1,5071,6503,0624,175 Income taxes1272,013-308414497Net Income attributable to owners of parent-915-3,5551,9502,5503,6615,800EPS (yen)-22.18-85.4146.8461.2587.95139.31Overseas sales6,4124,8684,0152,3172,100 Overseas sales ratio37.2%29.3%25.6%15.9%13.9%Shareholders’ equity11,7807,9829,95812,38615,840Net assets22,47326,21528,47716,38115,838Total assets56,25357,49354,32939,00236,972Equity ratio39.9%45.5%52.3%41.8%42.6%Capex9251,2741,6121,5141,0252,035Depreciation & amortization1,5451,4721,3611,2291,1871,180R&D expenses600518339400392541R&D expenses to sales ratio3.48%3.12%2.17%2.75%2.59%3.02%Year-end number of employees1,5061,3859359859861,025ROE-4.7%-14.6%7.1%11.4%22.9%ROA-4.0%-1.4%2.9%6.7%9.6%Operating income to sales ratio-10.4%-4.2%5.3%15.3%16.7%22.9%Dividend per share (yen)ーー3.05.020.040.0DPRーー6.4%8.2%22.7%28.7%Financial Data